SENZIME AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.82 SEK | +13.67% |
|
+14.43% | -8.21% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Senzime publ AB is a Sweden-based company engaged in the development, manufacture and marketing of biosensors for measuring metabolites in biological fluids, such as human blood and cell culture substrates for the pharmaceutical and healthcare segments. The Company focuses on the following application areas: medical diagnostic instruments, pharmaceutical industry, chemical processing, and food and beverage processing. As of December 31, 2011, the Company marketed three products, namely SENZ-100G, for continuous analysis of glucose in the fermentation solutions; SENZ-100L, for continuous analysis of lactate in fermentation solutions, and SENZ-200G, for continuous analysis of glucose in blood during intensive care.
Calendar
2024-05-06
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -8.21% | 74.46M | |
| -2.31% | 187B | |
| -3.20% | 106B | |
| -5.04% | 66.9B | |
| +0.20% | 49.45B | |
| +17.29% | 48B | |
| +4.06% | 40.84B | |
| +2.07% | 26.48B | |
| +2.36% | 26.25B | |
| +12.96% | 24.62B |
- Stock Market
- Equities
- SEZI Stock
- News Senzime AB
- Senzime Wins TetraGraph Order in US; Stock Surges
